Prolonged real-life experience with baricitinib in patients with moderate-to-severe atopic dermatitis
(2023) European Journal of Dermatology — Vol. 33, n° 6, p. 707-709 (2023)
Files
Details
- Authors
- Abstract
- (en) Baricitinib is an oral selective Janus-kinase (JAK) 1 and 2 inhibitor for the treatment of moderate-to-severe atopic dermatitis (AD). Its efficacy and safety have previously been demonstrated in clinical trials, but only in short-term real-life studies. We retrospectively collected real-life data from a monocentric adult patients cohort treated with baricitinib for moderate-to-severe AD in Belgium from January 2021 to May 2023. [...]
- Affiliations
Citations
De Greef, A., Ghislain, P.-D., & Baeck, M. (2023). Prolonged real-life experience with baricitinib in patients with moderate-to-severe atopic dermatitis. European Journal of Dermatology, 33(6), 707-709. https://doi.org/10.1684/ejd.2023.4618 (Original work published 2023)